Evicenter
Repatha (evolocumab) in Cardiovascular event risk reduction
Manufacturer
Amgen Inc.
Prescribing information
Repatha (opens in a new tab)
Questions
14
Last updated

All questions

Safety: Repatha (evolocumab) in cardiovascular event risk reduction

4 questions · 1 source

Safety evidence

Does Repatha affect memory or cognitive function (EBBINGHAUS)?

Note: In FOURIER, patients with established cardiovascular disease on statin therapy received REPATHA 140 mg every 2 weeks or 420 mg once monthly, or placebo.

Side effects

What are the most common side effects of Repatha in cardiovascular outcomes trials?

Note: The second passage concerns Trial 2 (VESALIUS-CV), in patients at high cardiovascular risk without a prior myocardial infarction or stroke.

Does Repatha increase the risk of diabetes?

Note: These figures are from FOURIER, a placebo-controlled trial in patients with established atherosclerotic cardiovascular disease with a median exposure of 24.8 months.

What did VESALIUS-CV show about Repatha's long-term safety?